University of Tübingen - Institute for Ophthalmic Research
Welcome,         Profile    Billing    Logout  
 1 Trial 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stingl, Katarina
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
BRIGHTEN, NCT04855045 / 2020-000535-45: An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.

Recruiting
2/3
15
Europe, Canada, RoW
sepofarsen, QR-110
ProQR Therapeutics
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration, Retinal Dystrophies
12/23
12/23
NCT06291935: Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Recruiting
1
6
Europe
VG901, AAV2.NN-CNGA1
ViGeneron GmbH
Retinitis Pigmentosa
12/25
12/25
NCT04639635: CNGB1 and Allied Disorders

Recruiting
N/A
20
Europe, US
No intervention, this is a natural history progression study
Columbia University, Michigan State University, Moorfields Eye Hospital NHS Foundation Trust, Universität Tübingen, Wills Eye, La Fondation Voir et Entendre, Ludwig-Maximilians - University of Munich
Retinitis Pigmentosa Associated With CNGB1 Mutations
01/25
01/26
NCT05294978: EyeConic: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
Optical coherence tomography (OCT)
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel
Retinal Dystrophies
12/24
12/25
NCT06323772: Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa

Recruiting
N/A
40
Europe
University Hospital Tuebingen
Retinitis Pigmentosa
03/27
03/27
RUSH1F, NCT04765345: Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

Active, not recruiting
N/A
40
Europe, Canada, US, RoW
Jaeb Center for Health Research, Usher 1F Collaborative, Marjorie C. Adams Foundation, Foundation Fighting Blindness
Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
06/27
06/27
NCT05809635: Study of BEST1 Vitelliform Macular Dystrophy

Recruiting
N/A
52
Europe, US
Natural History Study
Columbia University, Universität Tübingen, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, National Eye Institute (NEI)
Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
05/25
05/25
NCT05218928: Qualification for Cone-Optogenetics

Recruiting
N/A
1000
Europe, US, RoW
OCT
University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Retinal Dystrophies
04/22
12/22
Rindtorff, Andrea
BRIGHTEN, NCT04855045 / 2020-000535-45: An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.

Recruiting
2/3
15
Europe, Canada, RoW
sepofarsen, QR-110
ProQR Therapeutics
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration, Retinal Dystrophies
12/23
12/23
NCT06291935: Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Recruiting
1
6
Europe
VG901, AAV2.NN-CNGA1
ViGeneron GmbH
Retinitis Pigmentosa
12/25
12/25
GYROS, NCT05312736: Gyrate Atrophy Ocular and Systemic Study

Recruiting
N/A
45
Europe, Canada, US, RoW
Jaeb Center for Health Research, Conquering Gyrate Atrophy Foundation, Foundation Fighting Blindness
Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
12/28
06/29

Download Options